Clavulanic Acid Series API Market Sees New Momentum with Kaizen Bioscience’s 2025 NDA and Amoxyclav 625 mg Launch
According to market estimations, the clavulanic acid series API market, valued at US$ 385 million in 2023, is projected to reach US$ 777.66 million by 2034, driven by rising antibiotic resistance and R&D. North America leads, Asia-Pacific grows fastest, with potassium clavulanate and oral meds dominating.
Last Updated : 21 April 2026
Category: Therapeutic Area
Insight Code: 5284
Format: PDF / PPT / Excel